Lead Product(s): AXO-AAV-GM1
Therapeutic Area: Genetic Disease Product Name: AXO-AAV-GM1
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Axovant Gene Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 15, 2020
Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercialization.